We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Alligator Bioscience Ab | LSE:0RK9 | London | Ordinary Share | SE0000767188 | ALLIGATOR BIOSCIENCE ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 23.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Noncomml Resh Organizations | 61.9M | -248.59M | -1.1221 | -20.50 | 5.1B |
From May 2021 to May 2024
LUND, Sweden, April 1, 2022 /PRNewswire/ -- Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced the completion of the patient enrollment for the 600 mg dose cohort from Alligator's Phase I, first-in-human clinical trial with the 4-1BB (CD137) targeting drug candidate, ATOR-1017, which is being developed as a tumor-directed therapy for
advanced/metastatic cancer. The Phase I study with ATOR-1017 is an open-label, dose escalation study in patients with histologically confirmed, advanced and/or refractory solid cancer (NCT04144842). The primary objective of the study is to investigate the safety and tolerability of ATOR-1017, and to determine the recommended dose for subsequent Phase II studies.
The data indicate that for doses up to 600 mg, there were no significant safety concerns with stable disease as the best tumor response. Patient enrollment and treatment for the highest planned dose cohort, 900 mg, has commenced.
As previously announced in December 2021, results from the early readout for ATOR-1017 showed that the drug candidate has an encouraging safety profile. In this readout, there was no dose-limiting toxicity or severe immune-related adverse events (link to press release).
For further information, please contact:
Julie Silber, Investor Relations
Phone: +46 46-540 82 23
E-mail: jur@alligatorbioscience.com
About Alligator Bioscience
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator's pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4-1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out licensed programs include AC101, in phase II development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience's shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden.
For more information, please visit http://www.alligatorbioscience.com.
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/alligator-bioscience/r/alligator-bioscience-announces-completion-of-600-mg-dose-cohort-for-ator-1017--dose-escalation-and-e,c3537725
The following files are available for download:
https://mb.cision.com/Main/12681/3537725/1557924.pdf | Alligator ATOR 1017 Q1 press release ENG FINAL |
Copyright 2022 PR Newswire
1 Year Alligator Bioscience Ab Chart |
1 Month Alligator Bioscience Ab Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
